GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » Price-to-Owner-Earnings

Zogenix (Zogenix) Price-to-Owner-Earnings : (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zogenix Price-to-Owner-Earnings?

As of today (2024-04-26), Zogenix's share price is $26.68. Zogenix does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Zogenix's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Zogenix was 53.72. The lowest was 0.00. And the median was 29.33.


ZGNX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.385
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-26), Zogenix's share price is $26.68. Zogenix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $-4.07. Therefore, Zogenix's PE Ratio for today is At Loss.

As of today (2024-04-26), Zogenix's share price is $26.68. Zogenix's EPS without NRI for the trailing twelve months (TTM) ended in was $-4.07. Therefore, Zogenix's PE Ratio without NRI for today is At Loss.

During the past 13 years, Zogenix's highest PE Ratio without NRI was 27.58. The lowest was 0.00. And the median was 6.07.


Zogenix Price-to-Owner-Earnings Historical Data

The historical data trend for Zogenix's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix Price-to-Owner-Earnings Chart

Zogenix Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zogenix Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zogenix's Price-to-Owner-Earnings

For the Biotechnology subindustry, Zogenix's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zogenix's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zogenix's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Zogenix's Price-to-Owner-Earnings falls into.



Zogenix Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Zogenix's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=26.68/-5.05
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zogenix  (NAS:ZGNX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Zogenix Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Zogenix's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Zogenix (Zogenix) Business Description

Traded in Other Exchanges
N/A
Address
5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Executives
Erle T Mast director C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner director PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick director C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts director C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar officer: EVP & CHIEF COMMERCIAL OFFICER C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel officer: EVP/Chief Development Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer officer: EVP/Chief Medical Officer C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr director, officer: President and CEO [email protected] EMERYVILLE CA 94608
Mark C Wiggins director 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock director C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer director
Shawnte Mitchell officer: EVP, GC and Secretary 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith officer: EVP, CFO, Treasurer & Sec. 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5

Zogenix (Zogenix) Headlines

From GuruFocus

Zogenix Reports Granting of Inducement Awards

By Marketwired Marketwired 08-16-2021

Zogenix Reports Granting of Inducement Awards

By GuruFocusNews GuruFocusNews 11-17-2021

Zogenix Reports Granting of Inducement Awards

By GuruFocusNews GuruFocusNews 12-16-2021